Related Experiment Video
Updated: Mar 17, 2026
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Development of a Novel GABAB Receptor Modulator as an Alternative to Phenibut: Insights from Molecular Modeling and
Samson Olusegun Afolabi1, Maria A Netesa2, Aleksei V Kolobov1
1Laboratory of Chemoinformatics, Infochemistry Scientific Center, ITMO University, Saint Petersburg, 191002, Russia.
Introduction:
Phenibut, a GABAB receptor agonist, is used for anxiety and insomnia but is limited by side effects like drowsiness and withdrawal symptoms. This study aimed to identify a novel GABAB receptor modulator with improved efficacy and safety.
Methods:
A drug database of 15,000 compounds was screened using the Tanimoto similarity coefficient, identifying three candidates. Molecular docking and dynamics simulations assessed their binding affinity and stability with the GABAB receptor. The lead compound, 3-[(2-oxo-2- phenylethyl)amino]benzoic acid (C1), was tested in vivo using a stress-induced Wistar rat model (n=20, male, 200-250 g), with phenibut as a reference. Anxiety-like behaviour was evaluated via the elevated plus maze, and pharmacokinetic properties were analyzed.
Results:
C1 exhibited superior binding affinity (ΔGbind = -8.5 kcal/mol) and stability compared to phenibut (-8.0 kcal/mol). In vivo, C1 significantly increased open-arm time (110.80 ± 26.10 min) compared to phenibut (57.80 ± 9.40 min, p<0.05), indicating reduced anxiety-like behaviour. C1 also showed favourable oral bioavailability and blood-brain barrier permeability.
Discussion:
Consistently, C1 demonstrated superior performance compared to phenibut, suggesting its potential as a more effective alternative for GABAB receptor modulation.
Conclusion:
C1 is a promising alternative to phenibut, demonstrating enhanced anxiolytic effects and a favourable safety profile. Further studies are warranted to confirm its clinical potential.
More Related Videos
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
07:51Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
Published on: November 14, 2014
Related Concept Videos
01:15Drug Abuse and Addiction: Pharmacological Phenomena
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:29The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...